Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study for Patients With Relapsing Remitting Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: placeboDrug: dirucotide
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 218
- Registration Number
- NCT00869986
- Locations
- 🇧🇬
Military Medical Academy, Sofia, Bulgaria
🇷🇸Clinical Center of Serbia, Belgrade, Serbia
🇸🇰FNsP J A Reimana, Presov, Slovakia
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 113
- Registration Number
- NCT00867009
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reus, Spain
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT00862784
- Locations
- 🇪🇸
ImClone Investigational Site, Valencia, Spain
Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 612
- Registration Number
- NCT00861757
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT00857961
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 71
- Registration Number
- NCT00857454
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
- Conditions
- Erectile DysfunctionBenign Prostatic Hyperplasia
- Interventions
- Drug: PlaceboDrug: Tadalafil
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2011-07-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 606
- Registration Number
- NCT00855582
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY2428757Drug: Placebo for LY2428757Drug: TT223Drug: Placebo for TT223
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 131
- Registration Number
- NCT00853151
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT00849693
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalnepantla, Mexico
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 337
- Registration Number
- NCT00849901
- Locations
- 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine